Compare · ATNF vs NVO
ATNF vs NVO
Side-by-side comparison of 180 Life Sciences Corp. (ATNF) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATNF and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2811.4x ATNF ($65.1M).
- Over the past year, ATNF is up 587.9% and NVO is down 45.7% - ATNF leads by 633.5 points.
- NVO has hit the wire 8 times in the past 4 weeks while ATNF has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 1 for ATNF).
- Company
- 180 Life Sciences Corp.
- Novo Nordisk A/S
- Price
- $7.08-8.05%
- $41.01-4.51%
- Market cap
- $65.1M
- $183.15B
- 1M return
- +287.16%
- -10.44%
- 1Y return
- +587.86%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 0
- 8
- Recent ratings
- 1
- 25
180 Life Sciences Corp.
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ATNF
- SEC Form PRE 14A filed by 180 Life Sciences Corp.
- Chief Executive Officer Jordan Blair disposed of 200,000 shares (SEC Form 4)
- 180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- 180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by 180 Life Sciences Corp.
- SEC Form S-3ASR filed by 180 Life Sciences Corp.
- SEC Form S-3ASR filed by 180 Life Sciences Corp.
- SEC Form S-3ASR filed by 180 Life Sciences Corp.
- 180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care